Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)

Published:2017-05-09 Issue:7 Volume:47 Page:664-667
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Namikawa Kenjiro¹,Tsutsumida Arata¹,Mizutani Tomonori²,Shibata Taro²,Takenouchi Tatsuya³,Yoshikawa Shusuke⁴,Kiyohara Yoshio⁴,Uchi Hiroshi⁵,Furue Masutaka⁵,Ogata Dai⁶,Tsuchida Tetsuya⁶,Yamazaki Naoya¹

Affiliation:

1. Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo

2. JCOG Data Center/Operations Office, National Cancer Center, Tokyo

3. Department of Dermatology, Niigata Cancer Center Hospital, Niigata

4. Department of Dermatology, Shizuoka Cancer Center, Shizuoka

5. Department of Dermatology, Kyushu University Hospital, Fukuoka

6. Department of Dermatology, Saitama Medical University Hospital, Saitama, Japan

Funder

Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development

National Cancer Center Research and Development Fund

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/47/7/664/24356837/hyx063.pdf

Reference13 articles.

1. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684;Kirkwood;J Clin Oncol,1996

2. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma;Kirkwood;Clin Cancer Res,2004

3. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial;Eggermont;Lancet,2008

4. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma;Eggermont;J Clin Oncol,2012

5. Interferon alpha for the adjuvant treatment of cutaneous melanoma;Mocellin;Cochrane Database Syst Rev,2013

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antitumor activity of pegylated human interferon β as monotherapy or in combination with immune checkpoint inhibitors via tumor growth inhibition and dendritic cell activation;Cellular Immunology;2023-11

2. Adjuvant nivolumab therapy may not improve disease‐free survival in resected acral lentiginous melanoma patients: A retrospective case series;Dermatologic Therapy;2022-09-19

3. Utilization and survival benefit of adjuvant immunotherapy in resected high-risk stage II melanoma;Surgery in Practice and Science;2022-03

4. FeLV-infection: problems and prospects of vaccine prevention and interferon-therapy of feline leukemia;Russian Journal of Infection and Immunity;2021-09-20

5. Treatment of Advanced Melanoma: Past, Present and Future;Life;2020-09-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3